MDGL

Madrigal Pharmaceuticals, Inc.

220.07 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Madrigal Pharmaceuticals, Inc. stock is up 3.79% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.89% of the previous 17 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 60% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
13 May 14:50 21 Jun, 2024 145.00 CALL 5 6
14 May 13:42 19 Jul, 2024 200.00 CALL 10 52
14 May 14:17 21 Jun, 2024 220.00 CALL 32 53
15 May 18:56 21 Jun, 2024 160.00 CALL 5 49
16 May 13:30 18 Oct, 2024 180.00 PUT 30 0
16 May 16:28 17 Jan, 2025 195.00 CALL 5 21
17 May 18:04 17 May, 2024 250.00 PUT 10 360
17 May 18:06 21 Jun, 2024 250.00 PUT 10 181
17 May 18:46 17 Jan, 2025 300.00 CALL 30 248
17 May 18:46 17 Jan, 2025 300.00 CALL 95 248

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the. treatment of non-alcoholic steatohepatitis.

  • B. Riley
    Fri May 10, 08:43
    hold
    confirm
  • HC Wainwright & Co.
    Wed May 8, 15:30
    buy
    confirm
  • Citigroup
    Wed May 8, 15:15
    buy
    confirm
  • JP Morgan
    Wed May 8, 13:58
    buy
    confirm
  • Bank of America
    Mon Apr 22, 06:18
    sell
    initial